

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

- 1-4. (canceled)
5. (currently amended) A method of treating rejection of a grafted cell, tissue, or organ in a mammal comprising administering to ~~the~~ a mammal in need of such treating a composition comprising a purified heat shock protein which is substantially free of complexed antigenic molecule, wherein the heat shock protein is not cpn10 or hsp60.
6. (original) The method of Claim 5, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ.
7. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~, wherein the grafted cell, tissue, or organ is skin, liver, kidney, heart, bone marrow, pancreas, lung, cornea, cartilage, or a cell derived therefrom.
8. (original) The method of Claim 7, wherein the grafted cell or tissue is skin or a cell derived from skin.
9. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~, wherein the heat shock protein is mammalian.
10. (original) The method of Claim 9, wherein the heat shock protein is human.
11. (original) The method of Claim 9, wherein the heat shock protein is gp96.
12. (original) The method of Claim 9, wherein the heat shock protein is hsp70.
13. (original) The method of Claim 9, wherein the heat shock protein is hsp90.

14. (currently amended) The method of Claim ~~1, 2, 3, 4, 5~~, or 6, wherein the mammal is human.
15. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~, wherein the heat shock protein is autologous to the mammal.
16. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~, wherein the heat shock protein is not obtained from or syngeneic to the donor of the grafted cell, tissue, or organ.
- 17-19. (canceled)
20. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~, wherein the amount of the heat shock protein present in the composition is in a range of 5 µg to 5,000 µg.
21. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~, wherein the amount of the heat shock protein present in the composition is 100 µg or more.
22. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~, wherein the amount of the heat shock protein present in the composition is 200 µg or more.
23. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~ or 10, further comprising administering to the mammal a sample of cells or tissue obtained from the cell, tissue, or organ donor prior to administration of the heat shock protein.
24. (canceled)
25. (canceled)
26. (currently amended) The method of Claim ~~1, 2, 3, 4, or 5~~, wherein an additional molecule is not administered in or concomitantly with said composition, said additional molecule modulating the function of an immune system cell.
27. (withdrawn) The method of Claim 26, wherein the additional molecule is a monoclonal antibody.

- 28. (withdrawn) The method of Claim 26, wherein the additional molecule is a soluble receptor analogue.
- 29-40. (canceled)
- 41. (new) The method of claim 10, wherein the heat shock protein is gp96.
- 42. (new) The method of claim 10, wherein the heat shock protein is hsp70.
- 43. (new) The method of claim 10, wherein the heat shock protein is hsp90.